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Background: The aim of this study was to analyze the long-term survival of AML patients with CEBPA mutations.
Patients and methods: We investigated 88 AML patients with a median age of 61 years and (1) cytogenetically
normal AML (CN-AML), (2) monoallelic (moCEBPA) or biallelic (biCEBPA) CEBPA mutation, and (3) intensive induction
treatment. 60/88 patients have been described previously with a shorter follow-up.
Results: Median follow-up time was 9.8 years (95% CI: 9.4-10.1 years) compared to 3.2 and 5.2 years in our former
analyses. Patients with biCEBPA mutations survived significantly longer compared to those with moCEBPA (median
overall survival (OS) 9.6 years vs. 1.7 years, p = 0.008). Patients ≤ 60 years and biCEBPA mutations showed a favorable
prognosis with a 10-year OS rate of 81%.
Both, bi- and moCEBPA-mutated groups had a low early death (d60) rate of 7% and 9%, respectively. Complete
remission (CR) rates for biCEBPA- and moCEBPA-mutated patients were 82% vs. 70% (p = 0.17). biCEBPA-mutated
patients showed a longer relapse free survival (RFS) (median RFS 9.4 years vs. 1.5 years, p = 0.021) and a lower
cumulative incidence of relapse (CIR) compared to moCEBPA-mutated patients. These differences in OS and RFS
were confirmed after adjustment for known clinical and molecular prognostic factors.
Conclusions: In this long-term observation we confirmed the favorable prognostic outcome of patients with
biCEBPA mutations compared to moCEBPA-mutated CN-AML. The high probability of OS (81%) in younger patients
is helpful to guide intensity of postremission therapy.
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According to the current recommendations of the WHO
[1] the large and heterogeneous group of cytogenetically
normal AML (CN-AML) is further stratified by the
presence or absence of internal tandem duplications of
fms-related tyrosine kinase 3 (FLT3-ITD), mutations of
nucleophosmin (NPM1) and mutations in the CCAAT/
enhancer binding protein (C/EBP) alpha (CEBPA). In
fact, “AML with mutated CEBPA” has been classified as
its own category in the current WHO classification [1].* Correspondence: Friederike.Pastore@med.uni-muenchen.de
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unless otherwise stated.The gene encoding for the CCAAT/enhancer binding
protein-α (CEBPA) is located on chromosome 19 band
q13.11. It was first full-length cloned in 1997 [2]. The
CEBPA protein is 42 kDa of size. It is expressed in mye-
lomonocytic cells and upregulated in granulocytic differen-
tiation acting as a myeloid transcription factor. Mutations
of CEBPA in AML were first described in 2001 [3]. N-
terminal frameshift mutations lead to the overexpression
of a truncated 30 kDA isoform of CEBPA that suppresses
CEBPA function in a dominant negative way. C-terminal
mutations occur mainly in the basic Zipper (bZIP) domain
of CEBPA, and impair its function to homodimerize and
heterodimerize with other proteins as well as its DNA
binding [4]. CEBPA knock-out mice show a selective blockLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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hematopoietic cells differentiate regularly [5]. Mutations of
CEBPA have been shown to be associated with CN-AML
where they occur with frequencies of 8 -18% [6–10] and
with the French-American-British (FAB) subtypes M1 and
M2 [11].
CEBPA mutations can occur as monoallelic mutations
(moCEBPA) or as biallelic mutations (biCEBPA). Patients
with biCEBPA mutations usually have a C-terminal muta-
tion on one allele and an N-terminal mutation on the
other allele, resulting in a lack of CEBPA wildtype allele
expression [12,13]. We and others have reported earlier
that the positive prognostic impact on outcome is re-
stricted to patients with biCEBPA mutations [6,13–16].
Except for the studies of Taskesen [16] and Green [14] pa-
tient numbers with mutated CEBPA at diagnosis were
small (n < 50) and median follow-up times were <10 years
in the majority of the upper mentioned analyses.
The objective of this study was to investigate if the ef-
fect of moCEBPA versus (vs.) biCEBPA mutations on
outcome was true also in a longer follow-up period and




In this analysis we included all cytogenetically normal
(CN) AML patients with a monoallelic or a biallelic
CEBPA mutation treated within the two large multicenter
AML Cooperative group clinical studies, the AMLCG99 trial
[NCT00266136] and the AMLCG2008 trial [NCT01382147;
EUDRACT2007-003103-12] (randomization from July
1999 until December 2012; approved by the local insti-
tutional review boards) or in analogy to clinical studies
(treatment start from April 2000 until March 2013) in
our university hospital. We identified 88 patients fulfilling
these criteria. A subset of 60 of these patients have been in-
vestigated in previous publications with a shorter follow-
up [6,17].
Clinical parameters available at first diagnosis included
age, sex, Eastern Cooperative Group (ECOG) perform-
ance status [18], the French-American-British (FAB)
morphologic AML subtype, the origin of AML (de novo
vs. secondary or therapy-related AML), white blood cell
count (WBC), platelet count, haemoglobin level, lactate
dehydrogenase (LDH) level, myeloid blasts in the bone
marrow (BM) and in the peripheral blood (PB).
All patients were treated with intensive induction
chemotherapy. 76 patients (86%) were treated within the
AMLCG99 (n = 68) and AMLCG2008 (n = 7) and the
HD98-A study (n = 1). Details of the AMLCG99 study
and AMLCG2008 study have been published before
[19–21]. 12 patients (14%) were treated in analogy to the
AMLCG studies or with a classical “7 + 3” therapeuticregimen. The analysis included 19 patients who under-
went allogeneic stem cell transplantation (SCT): as con-
solidation in first CR (n = 7; 8% of patients), at the time
of relapse (n = 8; 9.1%) or primary refractory disease
(n = 4; 4.5%).The studies were approved by the ethics
committees of all participating institutions.
Cytogenetic and molecular analysis
Cytogenetic and molecular analyses were performed on
BM aspirates. For cytogenetic analyses ≥ 20 metaphases
were required. AML were classified as cytogenetically nor-
mal according to the guidelines of the international system
of cytogenetic nomenclature (ISCN) [22]. Mutations of
NPM1 [23], FLT3-ITD [24,25], FLT3-TKD [26], moCEBPA
and biCEBPA [6,10] and MLL-PTD [27] were analyzed as
previously published.
Statistical analysis
The outcome parameter overall survival (OS) was calcu-
lated from the date of first diagnosis to death. Relapse-
free-survival (RFS) was assessed in all patients having
achieved a complete remission (CR) or a CR with in-
complete recovery (CRi) according to the standard
guidelines of the ELN [28] and was calculated from the
date of CR/CRi until relapse or death. For patients who
underwent allogeneic SCT OS and RFS times were cen-
sored at the date of allogeneic transplantation.
For pairwise comparisons of dichotomous parameters
between moCEBPA and biCEBPA-mutated patients the
χ2-test/Fisher’s exact test was applied. The Mann–Whitney
U test was performed for the comparison of continuous
parameters between moCEBPA and biCEBPA-mutated
patients.
Comparisons of OS and RFS between patients with
moCEBPA and biCEBPA mutations were obtained apply-
ing the Kaplan Meier method and the log rank test. Me-
dian follow-up was calculated with the reversed Kaplan
Meier method. Univariable and multivariable Cox regres-
sion analyses were performed for OS and RFS to adjust
for potential imbalances of known clinical and molecular
prognostic factors summarized in the PINA [29]. To
evaluate the effect of biCEBPA vs. moCEBPA mutations
on AML-specific survival taking into account only deaths
related to AML, a competing risk analysis was performed
treating death unrelated to AML, and allogeneic SCT as
competing events. Likewise, the cumulative incidence of
relapse (CIR) was calculated for all patients in CR/CRi
treating death in CR and allogeneic SCT in first CR as
competing events. Cumulative incidence rates [30] and
hazard ratios (HR) [31] between the risk groups were cal-
culated and compared by the Gray test [32]. The compari-
son of OS in biCEBPA- vs. moCEBPA-mutated patients
was tested with a significance level of 5%. All other p-
values are descriptive. Analyses were performed using SPSS
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software package (R foundation for statistical computing,
Vienna, Austria).
Results
Comparison of moCEBPA- vs. biCEBPA-mutated patients
with respect to clinical and molecular parameters
Analyses were performed in 88 patients with CN-AML
and a mutation of CEBPA. Median age was 61 years, the
majority (86%) had de novo AML and an ECOG per-
formance status of 0–2 (96%). 45 patients showed a
biCEBPA mutation, 43 patients had a moCEBPA muta-
tion. Mutations of NPM1 and FLT3-TKD were present
in 19% and 6%, FLT3-ITD and MLL-PTD occurred in
25% and 1% of patients (Additional file 1: Table S1). 67%
of patients received a double induction therapy (Table 1).
Median follow-up time was 9.8 years (95% CI: 9.4-10.1).
4.5% of patients died within 30 days after start of ther-
apy. Median OS was 3.0 years (95% CI: 0.9-5.2) and me-
dian RFS in 67 patients who have achieved a CR/CRi
was 2.3 years (95% CI: 1.0-3.7) (Table 1). 28 (42%) of pa-
tients in CR/CRi relapsed and 51 (58%) of patients died.
There were less female patients in the biCEBPA
group compared to the moCEBPA group (44% vs. 72%)
(Additional file 1: Table S1). The presence of biCEBPA
mutations was associated with a higher rate of de novo
AML, a higher hemoglobin level, lower platelet count
and lower frequencies of additional mutations of NPM1,
FLT3-TKD or the presence of FLT3-ITD. All other clinicalTable 1 Therapy and outcome
All patients (N = 88) m
N % N
Number of induction cycles
1 29 33 1
2 59 67 2
Induction therapy regimen
In study 76 86 3
In analogy to study 12 14 7
Allogeneic SCT 19 22 1
in 1.CR 7 8 3
Primary refractory 4 5 3
At relapse 8 9 4
Early death until day 30 4 5 3
Early death until day 60 7 8 4
CR/CRi* 67 76 3
Median OS, 95% CI, years 3.0 (0.9-5.2)
Median RFS, 95% CI, years 2.3 (1.0-3.7)
*62 patients have achieved a CR; 5 patients have achieved a CRi;
Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein a
monoallelic mutation in the CCAAT/enhancer-binding protein alpha, N number, NAand molecular parameters as well as therapeutic regimen
including allogeneic SCT were evenly distributed between
patients with moCEBPA and biCEBPA mutations
(Table 1).
biCEBPA-mutated patients show a longer OS, RFS and a
lower CIR
Early death rates at day 30 and at day 60 were not differ-
ent between patients with biCEBPA and moCEBPA mu-
tations (Table 1).
In accordance with previous results, patients with biCEBPA
mutations survived significantly longer compared to
those with a moCEBPA mutations (median OS 9.6 years
vs. 1.7 years, p = 0.008) (Figure 1A). This survival bene-
fit was also evident in patients > 60 years (biCEBPA vs.
moCEBPA: 5-years OS: 37% vs. 11%, 10-years OS: 20% vs.
5%, p = 0.045; (Figure 2C)) and by trend in patients ≤
60 years (biCEBPA vs. moCEBPA: 5-years OS and 10-
years OS: 81% vs. 59%, p = 0.076 (Figure 2A)).
Consistent with the long follow-up, nine patients died in
CR of causes unrelated to AML. Results of competing risk
analyses treating death related to AML and death unre-
lated to AML as competing are illustrated in the supple-
ment (Additional file 1: Figure S1A). biCEBPA-mutated
patients displayed a lower cumulative incidence of death
related to AML compared to moCEBPA-mutated patients
(p = 0.028) (Additional file 1: Figure S1B).
37 patients (82%) with biCEBPA mutations and 30 pa-
tients (70%) with moCEBPA mutations achieved a CR/CRioCEBPA (N = 43) biCEBPA (N = 45) P
% N %
6 37 13 30 0.41
7 63 32 71
0.48
6 84 40 89
16 5 11




7 1 2 0.28
9 3 7 0.65
0 70 37 82 0.17
1.7 (0.7-2.7) 9.6 (NA) 0.008
1.5 (0.4-2.5) 9.4 (NA) 0.021
lpha, CR complete remission, CRi CR with incomplete revovery, moCEBPA
not applicable, SCT stem cell transplantation.
Figure 1 Outcome in patients with biCEBPA mutations compared to moCEBPA mutations. (A) OS in all patients (B) RFS in all patients in CR
(C) Cumulative incidence of relapse, death without relapse and allogeneic transplantation in 67 patients with a CR and (D) cumulative incidence
of relapse in moCEBPA or biCEBPA-mutated patients. Abbreviations: biCEBPA, biallelic mutation in the CCAAT/enhancer-binding protein alpha;
CI, confidence interval; CR, complete remission; moCEBPA, monoallelic mutation in the CCAAT/enhancer-binding protein alpha.
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a longer RFS compared to moCEBPA-mutated patients
(median RFS 9.4 years vs. 1.5 years, p = 0.021) (Figure 1B,
Table 1). A trend to a longer RFS in biCEBPA-mutated pa-
tients was seen in subgroups ≤ 60 and > 60 years of age
(p = 0.116 and p = 0.082, respectively) (Figure 2B and D).
CIR rates were lower in patients carrying biCEBPA com-
pared to moCEBPA mutations (5-year CIR rates: 40% vs.
60%, respectively; 10-year CIR rates: 45 vs. 65%, respect-
ively; p = 0.036) (Figure 1C,D). Median time from CR to
relapse was longer in the biCEBPA-mutated cohort vs. the
moCEBPA-mutated patients (not reached vs. 1.6 years,
p = 0.033). In the moCEBPA-mutated patients, 63%relapsed within the first and 94% within two years. In con-
trast, biCEBPA-mutated patients appeared to relapse later
during follow-up: only 33% relapsed in the first year, 67%
within the second year and 92% within the first three
years. In both cohorts, the majority of patient relapsed in
the first three years. Two patients - one with a biCEBPA
and one with a moCEBPA mutation - showed late relapses
after 7 and 8 years. In both cases, we do not have diagnos-
tic bone marrow aspirates to verify if these patients show
the same cytogenetic and mutational profile as at diagno-
sis. Due to the latency of many years and the preceding
chemo- and/or radiation therapy, we suspect that these
AML relapses might be therapy-associated AML.
Figure 2 OS and RFS in patients ≤/>60 years of age with biCEBPA mutations compared to moCEBPA mutations. (A) OS in patients
≤ 60 years (B) RFS in patients in CR≤ 60 years (C) OS in patients > 60 years (D) RFS in patients in CR > 60 years. Abbreviations: biCEBPA, biallelic
mutation in the CCAAT/enhancer-binding protein alpha; CI, confidence interval; CR, complete remission; moCEBPA, monoallelic mutation in the
CCAAT/enhancer-binding protein alpha.
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achievement of a CR according to therapy has been pro-
vided in the Additional file 1.Adjustment for co-occurring mutations and clinical
prognostic factors
Since FLT3-ITD and FLT3-TKD and NPM1 mutations,
were more common in moCEBPA-mutated patients, we
performed multivariable analyses to adjust for potential
confounding effects. The positive impact of biCEBPA vs.
moCEBPA mutations on outcome was confirmed when
adjusting for co-occurring FLT3-ITD and FLT3-TKD
mutations, NPM1 mutations, the PINAOS and PINARFS
[29] scores without biCEBPA mutations (Table 2) and inanalyses with FLT3-wildtype patients only (Additional
file 1: Figure S2).
Relapsed patients with biCEBPA and moCEBPA mutations
show similar outcomes
Treatment modalities at relapses (palliative vs. intensive
treatment; allogeneic SCT) were not different between
moCEBPA- and biCEBPA-mutated patients. Both CEBPA
cohorts, included similar amounts of patients≤ 60 years
(moCEBPA: 6/11; biCEBPA 4/9) and > 60 years (moCEBPA:
5/11; biCEBPA 5/9). Although, intensively treated biCEBPA-
mutated patients showed a tendency to a higher second CR
rate compared to moCEBPA-mutated patients (78% vs. 45%,
p = 0.142) survival after relapse was not different between
patients with moCEBPA or biCEBPA mutations (data not
Table 2 Cox Regression adjusted for additional markers
OS RFS
HR 95% CI p HR 95% CI p
biCEBPA versus moCEBPA (univariable analysis) 0.4 0.2-0.8 0.008 0.5 0.2-0.9 0.021
biCEBPA versus moCEBPA (adjusted for FLT3-ITD) 0.4 0.2-0.8 0.006 0.5 0.2-0.9 0.021
biCEBPA versus moCEBPA (adjusted for FLT3-TKD) 0.4 0.2-0.8 0.012 0.4 0.2-0.9 0.018
biCEBPA versus moCEBPA (adjusted for FLT3-ITD and FLT3-TKD) 0.4 0.2-0.8 0.006 0.4 0.2-0.8 0.012
biCEBPA versus moCEBPA (adjusted for FLT3-ITD, NPM1 mutations and interaction NPM1/FLT3-ITD) 0.2 0.1-0.5 <0.001 0.2 0.1-0.6 0.003
biCEBPA versus moCEBPA (adjusted for NPM1 mutations) 0.2 0.1-0.5 <0.001 0.2 0.1-0.6 0.002
biCEBPA versus moCEBPA (adjusted for PINAOS or PINARFS (both without biCEBPA)) 0.2 0.1-0.4 <0.001 0.2 0.1-0.6 0.001
Abbreviations: biCEBPA biallelic mutation in the CCAAT/enhancer-binding protein alpha, CI confidence interval, FLT3-ITD internal tandem duplication of the FLT3 gene,
FLT3-TKD mutation in the tyrosine kinase domain of the FLT3 gene, HR hazard ratio, interaction NPM1/FLT3-ITD, NPM1 positive/FLT3-ITD positive versus NPM1 negative
or FLT3-ITD negative, moCEBPA monoallelic mutation in the CCAAT/enhancer-binding protein alpha, NPM1, nucleophosmin gene, OS Overall survival, p p value,
PINAOS Prognostic Index for OS in cytogenetically normal AML [29], PINARFS Prognostic Index for RFS in cytogenetically normal AML [29], RFS Relapse-free survival.
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was only possible for patients treated with allogeneic SCT.
A detailed description of treatment at relapse, achievement
of a second CR and survival is given in the Additional file 1.
Discussion
According to the current WHO classification and the
ELN guidelines patients with mutated CEBPA represent a
cohort with a favorable prognosis [1,28]. We and others
have shown before, that this favorable prognostic effect is
restricted to the group of patients with biCEBPA, in con-
trast to moCEBPA [6] mutations. The aim of our current
analysis was to test if the favorable prognostic effect of
biCEBPA mutations was still evident within a (1) larger
patient cohort and (2) after a longer follow-up period.
Due to the low frequency of CEBPA mutations of about
8 - 18% in CN-AML, studies are often based on small pa-
tient numbers [6,13,15], which reduces statistical power.
Our study includes 88 patients, 75 of whom were treated
homogeneously within AMLCG99 and AMLCG2008
trials.
Except for the study of Green et al. [14] with a
medium follow-up for survivors of 11.7 years, median
follow-up in the published literature including our previ-
ous publication is mostly ≤ 5 years [6,13,15,16,33]. The
present analysis has a long medium follow-up of almost
10 years (9.8 years) and a maximum follow-up of
13.3 years. This allowed to detect late relapses.
In accordance with previous analyses [13–15], biCEBPA-
mutated AML patients displayed a significantly longer
OS compared to moCEBPA-mutated patients. Differ-
ences in OS might be caused by differences in early
death rate, achievement of a CR and RFS/incidence of
relapses. Patients with a biCEBPA mutation showed a
slightly lower early death rate at day 60 (6.7% versus
9.3%, Table 1) and a higher CR rate (CR rates: 82% ver-
sus 70%, p = 0.17, respectively) compared to patients
with a moCEBPA mutation. Interestingly, overall earlydeath rate until day 60 in all CEBPA-mutated patients
in our cohort was 8.0%, which is lower compared to
data in the literature of 10% to 16% [19,20,34]. These
differences might be caused by the fact that these stud-
ies included all cytogenetic risk groups and not only
CN-AML patients. Most importantly, we could clearly
see a better RFS in biCEBPA-mutated patients. This im-
proved RFS was also seen by others [14,15]. Moreover, we
could demonstrate a lower CIR in biCEBPA-mutated com-
pared to moCEBPA-mutated patients. However, to what
extent a lower early death rate, a higher CR rate or a longer
RFS caused the prolonged survival still remains open and
needs to be investigated in larger patient cohorts.
The favorable prognosis of biCEBPA-mutated AML
was most evident in patients ≤ 60 years who displayed a
10-years OS of 81% and a 10-years RFS of 66%.
In contrast to relapse in moCEBPA-mutated patients,
occurring in the majority of patients (63%) within the
first year after achievement of a CR, only about one
third of biCEBPA-mutated patients relapsed within the
first year. Almost all moCEBPA-mutated patients and
biCEBPA-mutated patients relapsed within the first three
years.
Interestingly, one patient with a biCEBPA-mutated AML
and one patient with a moCEBPA-mutated AML relapsed
more than 7 years after CR. To our knowledge, this is the
first case of such a late relapse in biCEBPA-mutated AML.
These late AML relapses might be therapy-associated and
display different cytogenetics and molecular mutational
patterns. Unfortunately, due to lack of material, we cannot
confirm the presence of a CEBPAmutation at relapse. Both
cases underline the importance of a long-term follow-up of
patients with AML and CEBPA mutations.
The long patient follow-up enabled us to detect patients
with late deaths (>5 years) unrelated to AML: Two pa-
tients with a moCEBPA mutation and one patient with a
biCEBPA mutation died in CR after 11.7 years (cause un-
known), 11.5 years (cause: development of a cancer of
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Thus, the inclusion of “AML unrelated death” helps to
better estimate prognosis, especially in elderly co-morbide
patients.
Schlenk et al. [35] recently showed in a large cohort of
124 CN-AML patients with biCEBPA mutations in first
CR, a significantly longer RFS, but similar OS, for those
patients receiving allogeneic or autologous transplant-
ation compared to chemotherapy only. We also found a
similar OS in our biCEBPA-mutated patients (n = 4)
receiving allogeneic SCT in first CR, compared to those
obtaining chemotherapy (n = 30), although we could
not detect an effect of allogeneic SCT on RFS, which
might be due to the small number of patients receiving
allogeneic SCT (data not shown). In accordance with
Schlenk et al. [35] we found a high second CR rate after
reinduction therapy of 78% in biCEBPA-mutated patients
treated with intensive protocols. Due to transplant-related
mortality, infections and a high relapse rate after the
second CR, this did not result in a longer OS compared to
relapsed moCEBPA-mutated patients. These results have
to be interpreted with caution since they are limited by
small patient numbers. Schlenk et al. [35] furthermore
showed that only relapsed patients treated with allogeneic
SCT, but not those treated with chemotherapy alone,
survived longer than 2 years. Our analyses - although
performed in a smaller patient cohort - are in line with
these results: In our cohort, patients with biCEBPA muta-
tions that have received allogeneic SCT at the time of re-
lapse are still alive (after 7.0 and 11.3 years) or have died
due to treatment related mortality, but not due to AML
relapse/refractory AML. In contrast, all 5 patients receiv-
ing chemotherapy at the time of relapse died (median OS
after relapse: 0.9 years).
Conclusion
In conclusion, our study with a long-term follow-up of
homogeneously treated CN-AML of almost 10 years
clearly showed that patients carrying biCEBPA mutations
have a substantially better OS and RFS as well as a rele-
vantly lower CIR compared to patients with moCEBPA
mutations. The excellent prognosis of younger AML pa-
tients with biCEBPA mutations (10-year OS of 81%) might
lead to a reduction of the intensity of postremission ther-
apy in this subgroup.
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